Income Before Tax

Income (Loss) from Continuing Operations Before Income Taxes, Domestic

Vertex Pharmaceuticals Income (Loss) from Continuing Operations Before Income Taxes, Domestic remained flat by 0.0% to $705.30M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 306.0%, from -$342.43M to $705.30M. Over 2 years (FY 2023 to FY 2025), Income (Loss) from Continuing Operations Before Income Taxes, Domestic shows relatively stable performance with a -4.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementIncome Statement
SectionIncome Before Tax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026

How to read this metric

Higher values indicate strong domestic operational performance.

Detailed definition

The pre-tax income or loss generated specifically from operations within the company's home country. This provides insig...

Peer comparison

Standard geographic segment reporting for multinational corporations.

Metric ID: ms_income_before_tax_domestic

Historical Data

3 years
 FY'23FY'24FY'25
Value$3.09B-$1.37B$2.82B
YoY Change-144.3%+306.0%
Range-$1.37B$3.09B
CAGR-4.4%
Avg YoY Growth+80.8%
Median YoY Growth+80.8%

Income (Loss) from Continuing Operations Before Income Taxes, Domestic at Other Companies

Frequently Asked Questions

What is Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, domestic?
Vertex Pharmaceuticals (VRTX) reported income (loss) from continuing operations before income taxes, domestic of $705.30M in Q4 2025.
How has Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, domestic changed year-over-year?
Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, domestic increased by 306.0% year-over-year, from -$342.43M to $705.30M.
What is the long-term trend for Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, domestic?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, domestic has grown at a -4.4% compound annual growth rate (CAGR), from $3.09B to $2.82B.
What does income (loss) from continuing operations before income taxes, domestic mean?
Pre-tax profit earned from domestic operations.